Source: Business Wire

Press Release: Wockhardt : Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Therapeutics Pipeline Review, H2 2015 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/msbwwx/vancomycinresista) has announced the addition of the "Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug tar

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Habil Khorakiwala's photo - Founder & CEO of Wockhardt

Founder & CEO

Habil Khorakiwala

CEO Approval Rating

81/100

Wockhardt is a pharmaceutical and biotechnology firm that manufactures injectables and lyophilised products. Read more